BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19443257)

  • 1. [Platelet transfusion: products, indications, dose, threshold and efficacy].
    Andreu G; Vasse J; Tardivel R; Semana G
    Transfus Clin Biol; 2009 May; 16(2):118-33. PubMed ID: 19443257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia.
    Hux BD; Martin LG
    J Vet Emerg Crit Care (San Antonio); 2012 Feb; 22(1):73-80. PubMed ID: 23016744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions to reduce platelet prophylactic transfusions in patients with hypoproliferative thrombocytopenia: providing patients with the full benefit.
    Vamvakas EC; Hitzler WE
    Clin Lab; 2013; 59(5-6):459-64. PubMed ID: 23865342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
    Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
    Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth SJ; Hyde C; Brunskill S; Murphy MF
    Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
    van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
    Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ
    Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet utilization and the transfusion trigger: a prospective analysis.
    Greeno E; McCullough J; Weisdorf D
    Transfusion; 2007 Feb; 47(2):201-5. PubMed ID: 17302764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative platelet transfusion: recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) 2003.
    Samama CM; Djoudi R; Lecompte T; Nathan-Denizot N; Schved JF;
    Can J Anaesth; 2005 Jan; 52(1):30-7. PubMed ID: 15625253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombocyte substitution. I. Indications and clinical use of thrombocyte transfusion].
    Anders O; Preussner S; Konrad H
    Z Gesamte Inn Med; 1986 Nov; 41(21):592-5. PubMed ID: 3825211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 1990 Feb; 4(1):291-311. PubMed ID: 2179213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus and controversies in platelet transfusion: trigger for indication, and platelet dose.
    Lozano M; Cid J
    Transfus Clin Biol; 2007 Dec; 14(6):504-8. PubMed ID: 18417400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transfusion of platelet concentrates].
    Bierling P
    Transfus Clin Biol; 2009 May; 16(2):190-4. PubMed ID: 19443251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet transfusion therapy.
    AuBuchon JP
    Clin Lab Med; 1996 Dec; 16(4):797-816. PubMed ID: 8974196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.